tradingkey.logo

Eton Pharmaceuticals Inc

ETON
View Detailed Chart
16.830USD
-0.160-0.94%
Close 12/26, 16:00ETQuotes delayed by 15 min
451.34MMarket Cap
LossP/E TTM

Eton Pharmaceuticals Inc

16.830
-0.160-0.94%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.94%

5 Days

+2.81%

1 Month

+3.95%

6 Months

+20.13%

Year to Date

+26.35%

1 Year

+28.97%

View Detailed Chart

Key Insights

Eton Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eton Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
49 / 158
Overall Ranking
126 / 4563
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
30.000
Target Price
+83.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Eton Pharmaceuticals Inc Highlights

StrengthsRisks
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 83.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 39.01M.
Fairly Valued
The company’s latest PE is -67.60, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.82M shares, decreasing 0.00% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.34M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.64.

Eton Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Eton Pharmaceuticals Inc Info

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Ticker SymbolETON
CompanyEton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
Websitehttps://etonpharma.com/

FAQs

What is the current price of Eton Pharmaceuticals Inc (ETON)?

The current price of Eton Pharmaceuticals Inc (ETON) is 16.830.

What is the symbol of Eton Pharmaceuticals Inc?

The ticker symbol of Eton Pharmaceuticals Inc is ETON.

What is the 52-week high of Eton Pharmaceuticals Inc?

The 52-week high of Eton Pharmaceuticals Inc is 23.000.

What is the 52-week low of Eton Pharmaceuticals Inc?

The 52-week low of Eton Pharmaceuticals Inc is 11.087.

What is the market capitalization of Eton Pharmaceuticals Inc?

The market capitalization of Eton Pharmaceuticals Inc is 451.34M.

What is the net income of Eton Pharmaceuticals Inc?

The net income of Eton Pharmaceuticals Inc is -3.82M.

Is Eton Pharmaceuticals Inc (ETON) currently rated as Buy, Hold, or Sell?

According to analysts, Eton Pharmaceuticals Inc (ETON) has an overall rating of Buy, with a price target of 30.000.

What is the Earnings Per Share (EPS TTM) of Eton Pharmaceuticals Inc (ETON)?

The Earnings Per Share (EPS TTM) of Eton Pharmaceuticals Inc (ETON) is -0.249.
KeyAI